        <DOC>
            	<DOCNO>s_1684_0_0</DOCNO>
            	<TEXT>Maybe this, and more legalizations like it across the US, will push $CHOOF back over $0.15 soon; bought a bunch of this stock back in May and couldn't be happier with the results, more than doubled my initial $$$.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_0_1</DOCNO>
            	<TEXT>Lets hope this is a part of Biden's new GREEN deal</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_1_0</DOCNO>
            	<TEXT>$CHOOF also looks to be coming out of a recent dip, good time to pump some guap into this pretty penny</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_2_0</DOCNO>
            	<TEXT>then imagine what tomorrow holds...to the moon baby</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_3_0</DOCNO>
            	<TEXT>Its been a tough stretch for everyone--when I was starting to get more serious with day trading, COVID hit hard and I learned many lessons the hard way.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_3_1</DOCNO>
            	<TEXT>Diversify, manage your risk, and stick to your intuition.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_4_0</DOCNO>
            	<TEXT>I'd also be curious to know, I'm surfing around for a platform that is slick for trading process but also has good analytics/screening/visual graphs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_4_1</DOCNO>
            	<TEXT>TradingView gets a bit cluttered, but I love the options for manipulating analytics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_4_2</DOCNO>
            	<TEXT>Would love to know what program/platform used here, and how it balances in-built capabilities for both trading and analysis.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_5_0</DOCNO>
            	<TEXT>I'm staying optimistic but fully agree with the assessment that the waves may be choppy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_5_1</DOCNO>
            	<TEXT>Steady wins the race folks</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_6_0</DOCNO>
            	<TEXT>I'm sure the Trump regime-era Xi Jinping and Vladimir Putin portraits they replaced will be sorely missed</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_7_0</DOCNO>
            	<TEXT>An interesting side-plot: "Pandemic Relief Bill Fulfills Bidens Promise to Expand Obamacare, for Two Years"</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_8_0</DOCNO>
            	<TEXT>$1.9tr could have gone a long way, but hey, fingers crossed for the big bucks in round #4</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_9_0</DOCNO>
            	<TEXT>well thanks for the benefit of the doubt at least</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_10_0</DOCNO>
            	<TEXT>$SDL $OGEN $ZMDTF $ETFM looking strong today</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_11_0</DOCNO>
            	<TEXT>Cradle-to-Cradle Paradigm</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_11_1</DOCNO>
            	<TEXT>Cradle-to-Cradle is a design paradigm that mimics nature in pioneering the safe and potentially infinite circulation of materials and technologies in cycles of consumption of production.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_11_2</DOCNO>
            	<TEXT>Its not just recycling, but upcycling.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_11_3</DOCNO>
            	<TEXT>In a way similar to permaculture's obvious applications to the agricultural sector, cradle-to-cradle design could totally revolutionize how we conceptualize industrial design.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_11_4</DOCNO>
            	<TEXT>Given the current ClimateAction/NetZero narrative, I think that Cradle-to-Cradle thinking should start playing a more important role in how we adapt environmentalism to industry and tech.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_11_5</DOCNO>
            	<TEXT> https://preview.redd.it/g70qonb7oeo61.png?width=1100 amp;format=png amp;auto=webp amp;s=72eadb858db887c5d3d294b349b7ef1af57f82a9</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_12_0</DOCNO>
            	<TEXT>If you think getting an AR-15 should be easier than casting a vote, you don't really believe in democracy</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_13_0</DOCNO>
            	<TEXT>Its all part of the Green New Deal folks, no coincidence in the name</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_14_0</DOCNO>
            	<TEXT>Hang in there mate this too shall pass</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_15_0</DOCNO>
            	<TEXT>ZoomD, a martech pennystock is entering trading today riding on an announcement that its launching sale operations in India (the world's potentially largest "free market" I might add).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_15_1</DOCNO>
            	<TEXT>Given today's wave of red, keep an eye on $ZOMD $ZMDTF during trading today</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_16_0</DOCNO>
            	<TEXT>Musing on ZoomD</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_16_1</DOCNO>
            	<TEXT>**ZoomD ($ZOMD $ZMDTF) is an interesting martech/SaaS penny trading on TSXV and OTC**.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_16_2</DOCNO>
            	<TEXT>I've been watching this ticker jump around in tandem with the news cycle, and wanted to share a few personal observations: * **From a technical angle, both tickers seem to be edging against resistance** at $0.7 for $ZOMD and $0.6 for $ZMDTF (see graph, lines in black=resistance).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_16_3</DOCNO>
            	<TEXT>This follows a big jump in mid-February, followed by a month of correction. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_16_4</DOCNO>
            	<TEXT>Now for some fundamental analysis.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_16_5</DOCNO>
            	<TEXT>I've been watching the news cycle, and ZoomD has nothing but positive press**\--a new deal in the Philippines, new DSP service, and today the announcement that they're launching sale ops in India.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_16_6</DOCNO>
            	<TEXT>These are all clear signs of growth-potential and an aggressive player unafraid to enter the global market. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_16_7</DOCNO>
            	<TEXT>I'm holding existing shares and adding some more in expectation of both tickers breaking through their resistance lines** once the markets begin to improve across the board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_16_8</DOCNO>
            	<TEXT>There's been a lot of volatility lately, and I have the feel come calmer seas, ZoomD will have the momentum to punch through for a potential breakout. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_16_9</DOCNO>
            	<TEXT>Would love to hear other thoughts or takes; do your own DD, this is my personal analysis**  https://preview.redd.it/ydzzkta1k8p61.png?width=1071 amp;format=png amp;auto=webp amp;s=774e51a374783c48393495bf3d893f9dd5550ae3</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_17_0</DOCNO>
            	<TEXT>InnoCan Q4 2020 Report Analysis</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_17_1</DOCNO>
            	<TEXT>InnoCan ($INNO $INNPF $IP4) is just one of the many firms that released their Q4 2020 Financial statements.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_17_2</DOCNO>
            	<TEXT>I've been following this CBD penny for a while now, and wanted to share some of my personal insights/analysis on the statements (see link to Yahoo article below) * Expenses for 2020 were largely accounting costs rather than operational expenses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_17_3</DOCNO>
            	<TEXT>Much of the $5 million recorded by the firm was the result of warrants issued previously, the value of which has increased with their stock value over 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_17_4</DOCNO>
            	<TEXT>So in layman's terms, "real" expenses that actually impact cash-on-hand are far lower. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_17_5</DOCNO>
            	<TEXT>From a fundamentals angle, InnoCan has never looked stronger.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_17_6</DOCNO>
            	<TEXT>In recent months, they've announced a slew of new patents, high-caliber personnel, clinical trials, expansion to overseas markets, and a successful manufacturing run in the US. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_17_7</DOCNO>
            	<TEXT>Consider collectively, these are all strong signs of growth-potential for a CBDPharma innovator.**</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_17_8</DOCNO>
            	<TEXT>Source: [https://www.yahoo.com/now/innocan-reports-q4-2020-financial-070000190.html](https://www.yahoo.com/now/innocan-reports-q4-2020-financial-070000190.html)  https://preview.redd.it/bsdu5vt3nlq61.png?width=1074 amp;format=png amp;auto=webp amp;s=53faa5423b859ead4a0c20cfe02f156e8311323a</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_18_0</DOCNO>
            	<TEXT>And the chatter in Washington is that the Senate is preparing legislating for federal legalization.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_18_1</DOCNO>
            	<TEXT>This would be the real game changer, because then cannabis/CBD firms won't have to deal with the federal financial restrictions currently in place on the industry.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_18_2</DOCNO>
            	<TEXT>Lets hope its sooner rather than later!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_19_0</DOCNO>
            	<TEXT>DD=Do or Die</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_20_0</DOCNO>
            	<TEXT>$SOS is hop-scotching downhill this morning, interested to see where we end up market close.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_20_1</DOCNO>
            	<TEXT>Currently at $5.38 and tanking...Takes?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_21_0</DOCNO>
            	<TEXT>Takes two to tango I guess...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_22_0</DOCNO>
            	<TEXT>What are $XL's long term prospects/how could they be compared to $PLUG and $TSLA?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_23_0</DOCNO>
            	<TEXT>$INNO up 7%, accelerating growth differential since market open.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_23_1</DOCNO>
            	<TEXT>This may be a break-out in progress, seems to be motivated by more positive moves in the fundamentals department [https://finance.yahoo.com/news/richard-serbin-former-johnson-johnsons-200000639.html](https://finance.yahoo.com/news/richard-serbin-former-johnson-johnsons-200000639.html)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_24_0</DOCNO>
            	<TEXT>$CHOOF, another CBD/Cannabis penny, likewise up a whomping 8% since market open</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_25_0</DOCNO>
            	<TEXT>I recently saw a pic of satellite imagery that resembled this level of resolution, was of a stretch of desert along the Iraq/Syria border, and you could literally see the texture of the sand.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_25_1</DOCNO>
            	<TEXT>Very very cool map, the likes of which will be far more widely accessible to the general public soon enough</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_26_0</DOCNO>
            	<TEXT>Word in war studies circles is that the war between Azerbaijan and Armenia of this past fall was decided by the latter's strategic use of drones.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_26_1</DOCNO>
            	<TEXT>In fact, drone warfare is a defining facet of multidomain warfare.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_26_2</DOCNO>
            	<TEXT>In a nutshell, the market for drones, and by extension, anti-drone tech is expected witness extreme growth over the next decade.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_26_3</DOCNO>
            	<TEXT>I'll be looking into this firm Kwesset and other competitors, I've got the gut feeling this is a sector that is going to see some interesting upward trends.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_27_0</DOCNO>
            	<TEXT>Morning BioTech Plays</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_27_1</DOCNO>
            	<TEXT>**MEREO Biopharma ($MREO) and Oncolytics Biotech (ONCY) are two biopharma pennystocks that are giving off strong "BUY" ratings from a technical perspective.**</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_27_2</DOCNO>
            	<TEXT>I'll let you ladies and gentlemen do your own fundamental DD, but as y'all can see in the graph, MREO is riding comfortably above ALL EMA lines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_27_3</DOCNO>
            	<TEXT>The ticker seems to be undergoing a nice and steady correction after a slip-and-rebound in late March.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_27_4</DOCNO>
            	<TEXT>ONCY is also riding above its EMAs, though has noticed more intra-day volatility than MEREO and thus may carry some more risk.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_27_5</DOCNO>
            	<TEXT>Nonetheless, given general projections for the biopharma sector and these two guys performance over recent weeks, I'm getting strong green vibes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_27_6</DOCNO>
            	<TEXT>do your own research and DD, this is just my personal take.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_27_7</DOCNO>
            	<TEXT>Happy trading today folks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_27_8</DOCNO>
            	<TEXT> https://preview.redd.it/1c4vmawpwxr61.png?width=1066 amp;format=png amp;auto=webp amp;s=578dd12626ad64ca52d862e8b9d608e05efde19c</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_28_0</DOCNO>
            	<TEXT>Let me know when I can pay student debt in Bitcoin and then we'll be talking</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_29_0</DOCNO>
            	<TEXT>My guess is we'll be witnessed many more acquisitions in the CBD/Cannabis sector in the next couple of years as the industry as a whole consolidates</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_30_0</DOCNO>
            	<TEXT>Hey man, really appreciate the analysis!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_30_1</DOCNO>
            	<TEXT>Do you have graphs/visuals illustrating the Fibonacci/resistance/support marks?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_30_2</DOCNO>
            	<TEXT>Helps us visual learners/understanders out there.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_30_3</DOCNO>
            	<TEXT>And otherwise keep the great insights coming!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_31_0</DOCNO>
            	<TEXT>$[INNO.CN](https://INNO.CN) (CBD penny) up 7.3% so far today, riding off a solid day of gains yesterday as well</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_32_0</DOCNO>
            	<TEXT>What goes up most come: \_\_\_\_\_?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_33_0</DOCNO>
            	<TEXT>I'm for one am impatiently waiting for the headline "Saudi oil fund makes historic investment in solar energy infrastructure"....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_34_0</DOCNO>
            	<TEXT>Can someone break down for me wtf is happening with $SPRWF; up 53% and trading at like 3.5X its avg.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_35_0</DOCNO>
            	<TEXT>I'd be interested to read said article, that said I'm not sure how energy efficient hydrogen vs. solar is at the current stage in the tech's development/potential for up-scaling and application to a large population.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_35_1</DOCNO>
            	<TEXT>Obv bc the Saudi's have limitless carbon-energy to experiment with in hydrogen R amp;D this is a viable option at the moment, but solar may ultimately be more cost effective and applicable on a mass-scale.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_36_0</DOCNO>
            	<TEXT>Em actually was talking about Oncolytics (ONCY), Oncocyte is OCX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_36_1</DOCNO>
            	<TEXT>But thanks for the resources in any event, these guys look like a very cool biotech firm!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_37_0</DOCNO>
            	<TEXT>After a tough week for the ad/marTech tickers, finally some Thursday afternoon momentum $PUBM $HUBS $FOUR $ACUIF $NET</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_0</DOCNO>
            	<TEXT>2021: Year of the AdTech/MarTech Surge?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_1</DOCNO>
            	<TEXT>About a year ago, right when COVID paralyzed the world economy, CEO Jeff Green (Trade Desk) was quoted as stating:  gt;Everybody becomes more data-driven and more agile during a recovery, because every dollar has to count, Green said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_2</DOCNO>
            	<TEXT>So thats when thats when it really accelerated for us.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_3</DOCNO>
            	<TEXT>So we were disproportionately hurt in the first month.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_4</DOCNO>
            	<TEXT>And weve been disproportionately benefiting ever since.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_5</DOCNO>
            	<TEXT>Fast forward a year, and we are well into the period where Trade Desk--and other firms from across the adTech/marTech--are witnessing said disproportionate benefits.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_6</DOCNO>
            	<TEXT>Combine this assessment with forecasts predicting the digital adTech field will see massive growth in coming years, and the voilah--we have a ripe window of opportunities for investors and traders looking to take advantage of an emerging trend with significant growth potential for years to come.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_7</DOCNO>
            	<TEXT>Here are some of my portfolios adTech picks, from penny stocks to large-caps: **ZoomD ($ZOMD $ZMDTF)** is a marTech/SaaS pennystock trading OTC and on TSXV.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_8</DOCNO>
            	<TEXT>Though the firm has witnessed a minor slip in share price last week, this was shared by stocks across the marTech/adTech field.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_9</DOCNO>
            	<TEXT>I believe ZoomD is riding on strong fundamentals, such as: * Expansion to new geographic and digital markets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_10</DOCNO>
            	<TEXT>ZoomD has recently announced a slew of new deals from clients as diverse as TikTok and a Philippine-based media group.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_11</DOCNO>
            	<TEXT>These are signs of a robustness and upward momentum. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_12</DOCNO>
            	<TEXT>All-star management team.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_13</DOCNO>
            	<TEXT>Omri Argaman, co-founder and CMO has +15 years of experience in the field.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_14</DOCNO>
            	<TEXT>He is joined by other veteran mar/adTech insiders, explaining the firms recent strong showing in adapting to fast-changing market conditions. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_15</DOCNO>
            	<TEXT>Given these facts and the general hit adTech took as a sector last week, I think ZoomD is bound for a strong rebound.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_16</DOCNO>
            	<TEXT>Though a pennystock and thus volatile, my assessment is that this is an ideal time to buy-the-dip.** **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_17</DOCNO>
            	<TEXT>Zuora ($ZUO)** Zuora sells a subscription management[ SaaS](https://en.wikipedia.org/wiki/SaaS) platform for businesses utilizing a subscription-service model.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_18</DOCNO>
            	<TEXT>The Zuora Central platform lets companies keep track of subscription payments, billing, collections, pricing, product catalogs, and accounting.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_19</DOCNO>
            	<TEXT>In addition to Zuora Central, Zuora's four primary SaaS applications are Zuora Billing, for recurring billing operations; Zuora Revenue, for revenue recognition; Zuora CPQ, sales quoting for subscription businesses; and Zuora Collect, for payment collections Investors can expect some modest growth from the company in the current first quarter of fiscal 2022.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_20</DOCNO>
            	<TEXT>Zuora's management said last month that Q1 sales will be $79 million at the midpoint of guidance, which would represent a 7% year-over-year increase. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_21</DOCNO>
            	<TEXT>If $ZUO is a strong BUY for Berenberg analyst Andrew DeGasperi, Ill have to agree.** **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_22</DOCNO>
            	<TEXT>SalesForce ($CRM)** Cloud-based customer relationship management (CRM) solutions provider salesforce.com has everything needed for a top-notch player in the adTech field.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_23</DOCNO>
            	<TEXT>Without digging too deeply into the weeds, CRM software is used by consumer-facing businesses to handle simple functions like logging client information and handling service issues and more complex things like overseeing online marketing campaigns and using predictive analysis to suggest which clients might purchase new products or services.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_24</DOCNO>
            	<TEXT>It's of obvious benefit to the service industry, and it is also finding a growing number of clients in manufacturing and finance, to name a few examples.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_25</DOCNO>
            	<TEXT>According to a report from Fortune Business Insights, global CRM revenue is expected to grow from $47.8 billion in 2019 to $113.5 billion by 2027.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_26</DOCNO>
            	<TEXT>That's a whopping 12% growth rate. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_27</DOCNO>
            	<TEXT>Its a more expensive buy (\~$230, at the time of writing) , but SalesForce has (in my humble opinion) titanic potential.**</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_38_28</DOCNO>
            	<TEXT>https://preview.redd.it/xukyomg43js61.jpg?width=960 amp;format=pjpg amp;auto=webp amp;s=c478d104d9fd4a2933fa20c1cf02603190924fc6</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_39_0</DOCNO>
            	<TEXT>2021: Year of the AdTech/MarTech Surge?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_40_0</DOCNO>
            	<TEXT>2021: Year of the AdTech/MarTech Surge?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_41_0</DOCNO>
            	<TEXT>Judging by your initial picks, looks like you're off to a good start.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_41_1</DOCNO>
            	<TEXT>One way I've found helpful in diversifying my portfolio for any sector is to think about 1) applications, and 2) growth potential.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_41_2</DOCNO>
            	<TEXT>In other words, try to branch out to related subfields in tech (e.g. AI, Quantum-readiness, vehicle automation, SaaS) that you see exploding over the months and years to come.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_41_3</DOCNO>
            	<TEXT>For ideas, sometimes I scroll through big ARK's holdings for ideas on disruptive trends and the firms catalyzing them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_42_0</DOCNO>
            	<TEXT>I'm not sure what's more disturbing--the war Putin is waging on his own people (Navalny, crushing civil rights) or the wars Putin is waging on the rest of the world, from Syria to Ukraine.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_43_0</DOCNO>
            	<TEXT>I so delight in the awkwardness of regime-corporate ties in China.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_43_1</DOCNO>
            	<TEXT>I think we're watching a transition in terms of how closely Chinese corporate interests (SOEs and POEs alike) and internal affairs are manipulated by the CCP.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_43_2</DOCNO>
            	<TEXT>I fear that the age of grinning Jack Mas will soon be replaced by a scowling Xi Jinpings.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_43_3</DOCNO>
            	<TEXT>In a nutshell, this latest move is part and parcel of the massive re-centralization taking place across multiple planes of Chinese society in recent years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_44_0</DOCNO>
            	<TEXT>Above and beyond 12% return (which is very respectable), I can rattle off more than one reason I sure as heck hope it wont be 2020 every year...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_0</DOCNO>
            	<TEXT>BioTech Firms Applying Cell-Therapy to Critical Limb Ischemia</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_1</DOCNO>
            	<TEXT>Critical Limb Ischemia (CLI) is a severe obstruction of the arteries which markedly reduces blood flow to the extremities (hands, feet, and legs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_2</DOCNO>
            	<TEXT>It is a rare though serious condition that requires immediate treatment to re-establish blood flow to the affected area or areas (most patients with CLI have multiple arterial blockages).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_3</DOCNO>
            	<TEXT>Treatment for CLI can be quite complex and individualized, but the overall goal should always be to reduce the pain and improve blood flow to save the leg.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_4</DOCNO>
            	<TEXT>The number one priority is to preserve the limb.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_5</DOCNO>
            	<TEXT>Advances in biotechnology, and in particular, cell therapy innovations, are revolutionizing the available avenues for treatment of this condition.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_6</DOCNO>
            	<TEXT>BioTech and cell therapy are expected to witness exponential growth over the coming decade, and II wanted to take the time to highlight a few of the markets leading players in terms of applying cell-therapy solutions to CLI: **Medtronic ($MDT)** Medtronic, is among the world's largest medical technology, services and solutions companies alleviating pain, restoring health and extending life for millions of people around the world.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_7</DOCNO>
            	<TEXT>Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_8</DOCNO>
            	<TEXT>The company is focused on collaborating with stakeholders around the world to take healthcare to new heights.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_9</DOCNO>
            	<TEXT>Medtronic PLCs MDT shares reached a new 52-week high of $121.81 on Apr 6, before closing the session marginally lower at $121.15.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_10</DOCNO>
            	<TEXT>The stock has gained 4.6% since its third-quarter earnings announcement on Feb 23.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_11</DOCNO>
            	<TEXT>The company is witnessing an uptrend in stock price, prompted by the recent slew of product approvals across business segments, which in turn is enabling it to gain strong market share Multiple analysts have recently earmarked MDT as a strong buy; on this assessment, I must concur. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_12</DOCNO>
            	<TEXT>Pluristem ($PSTI)** Pluristem Therapeutics Inc operates as a bio-therapeutics company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_13</DOCNO>
            	<TEXT>It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders Pluristem is currently being covered by 5 analysts, and the consensus rating is Buy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_14</DOCNO>
            	<TEXT>The range between the high target price and low target price is between 10 and 6 calculating the average target price we see 8.6.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_15</DOCNO>
            	<TEXT>With the stocks previous close at 6.18 this would indicate that there is a potential upside of 39.2%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_16</DOCNO>
            	<TEXT>The 50 day MA is 8.72 and the 200 moving average now moves to 9.25.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_45_17</DOCNO>
            	<TEXT>The company has a market cap of $173m.  https://preview.redd.it/ymy7eais9qs61.png?width=301 amp;format=png amp;auto=webp amp;s=6c1b5a47bcf245cd893301447130000e39875001</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_46_0</DOCNO>
            	<TEXT>BioTech Firms Applying Cell-Therapy to Critical Limb Ischemia</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_47_0</DOCNO>
            	<TEXT>BioTech Firms Applying Cell-Therapy to Critical Limb Ischemia</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_48_0</DOCNO>
            	<TEXT>Another fact to conider for BABA in the long-term is the future of CCP-corporate relations domestically within China.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_48_1</DOCNO>
            	<TEXT>The current leadership, under the helm of Xi Jinping, look to be tightening restrictions on the Chinese economy and the major players therein.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_49_0</DOCNO>
            	<TEXT>$INNO and $SPRWF are bullish af premarket, both hit ATHs last week</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_50_0</DOCNO>
            	<TEXT>MDCN up 26% premarket</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_51_0</DOCNO>
            	<TEXT>Remaking the South, one dispensary at a time</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_0</DOCNO>
            	<TEXT>DD/Analysis of Innocan's ATH</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_1</DOCNO>
            	<TEXT>Innocan is a CBD pharma pennystock I've been holding onto for several month at this point.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_2</DOCNO>
            	<TEXT>I've continued to witness very solid returns from this stock ($INNO, trading on CSE) and its other tickers ($IP4.F and $INNPF), and wanted to share through a bit of Reddit DD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_3</DOCNO>
            	<TEXT>Since the beginning of April, INNO stock has risen nearly 60%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_4</DOCNO>
            	<TEXT>The dominant consensus amongst most analysts is that Innocan is a buy/strong buy option.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_5</DOCNO>
            	<TEXT>For chart-lovers, take a look at the graph below (1M) for substantiation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_6</DOCNO>
            	<TEXT>From a fundamentals perspective, Innocan has been riding on a wave of positive news.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_7</DOCNO>
            	<TEXT>I noticed a Yahoo Finance article this morning, which I'll excerpt here:  gt;On Monday, investors saw Canadian-Israeli biotech company InnoCan Pharma (CNSX: $INNO, $INNPF, $IP4) stock rise more than 35%, the companys potential continues to grow with their upcoming commercialization in The United States  amp; Europe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_8</DOCNO>
            	<TEXT> gt;  gt;This week, as many major blue-chip stocks fell several points to more realistic evaluations, shares of Canadian-Israeli pharmaceuticals company InnoCan Pharma (CNSX: INNO) surged from $0.35 to $0.60 CAD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_9</DOCNO>
            	<TEXT>The company specializes in merging cannabinoids (CBD), unique ingredients, and smart delivery platforms to create pain-relieving products.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_10</DOCNO>
            	<TEXT>As InnoCans potential and now stock continue to rise, here is what investors should consider before pressing play.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_11</DOCNO>
            	<TEXT> gt;  gt;Last month, the InnoCan announced it new patent application for an anti-itch product with cannabinoid and effective ingredients to provide relief for insect bites, rash, cuts, burns or relevant allergen exposure.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_12</DOCNO>
            	<TEXT>The therapeutic market for pruritus relief products is worth tens of billions of dollars in commercial profit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_13</DOCNO>
            	<TEXT> gt;  gt;Unlike most companies in the field, InnoCan Pharma was formed by prominent players in the pharmaceuticals field.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_14</DOCNO>
            	<TEXT> gt;  gt; InnoCan has now set its sights on commercialization in major markets, beginning with its approvals from the Food and Drug Administrations in The United States and Europe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_15</DOCNO>
            	<TEXT> gt;  gt;Source: [https://news.yahoo.com/innocan-pharma-surge-record-highs-115935106.html](https://news.yahoo.com/innocan-pharma-surge-record-highs-115935106.html) Some details for this recap that stand out to me: 1) Innocan is distinguishing itself as an emerging power-player in the CBD market by leveraging its significant scientific and pharmaceutical expertise.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_16</DOCNO>
            	<TEXT>This isn't just another CBD gummie maker, but an innovative firm that is truly paving new foundations in CBD tech/applications.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_17</DOCNO>
            	<TEXT>2) Symmetry between conclusions of technical and fundamental DD; Innocan's earnings and most recent Q4 results show that strong financials undergird the company as it expands its products into new markets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_18</DOCNO>
            	<TEXT>I would welcome any thoughts on this bit of analysis, as well as insights on another worthwhile CBD-pennies trading in Canada.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_52_19</DOCNO>
            	<TEXT>https://preview.redd.it/d67rneratit61.png?width=1073 amp;format=png amp;auto=webp amp;s=0fc54a7fd0aea3bf3b737742588d75b96e5ba2db</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_53_0</DOCNO>
            	<TEXT>$INNO (CBD pharma, CSEX) +7.84%, bit ATH earlier this week and is riding a wave of buys</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_54_0</DOCNO>
            	<TEXT>I've got a feeling that we'll be seeing some green from $APHA today after solid consensus emerged from shareholders re the merger w/ Tilray ($TLRY)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_55_0</DOCNO>
            	<TEXT>I agree, as the ridiculous number of current CBD firms/startups begins to narrow down and consolidate, I have a feeling Innocan is already moving to the head of the pack.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_55_1</DOCNO>
            	<TEXT>And again, their pharma know-how/scientific capital already give them an edge over other CBD companies</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_56_0</DOCNO>
            	<TEXT>Galectin Therapeutics (GALT) DD/April Volatility Analysis</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_56_1</DOCNO>
            	<TEXT>Galectin Therapeutics Inc ($GALT) is a clinical stage biopharmaceutical company that engages in the research and development of therapies for fibrotic, cancer, and other diseases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_56_2</DOCNO>
            	<TEXT>The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_56_3</DOCNO>
            	<TEXT>It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_56_4</DOCNO>
            	<TEXT>The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_56_5</DOCNO>
            	<TEXT>GALT's chart has been following a downward channel pattern since late September or so.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_56_6</DOCNO>
            	<TEXT>That trend may be changing, as of April, however.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_56_7</DOCNO>
            	<TEXT>On April 6, GALT announced the launch of a new program that led to a 35% jump in a single day's trading.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_56_8</DOCNO>
            	<TEXT>Yesterday (April 19), share price also jumped by 27% following the announcement that Ben Carson (yep, that one) joined the crew as a "special consultant."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_56_9</DOCNO>
            	<TEXT>In short, GALT has had some rather dramatic swings from bullish to bearish to back in recent weeks, and I'm buckling up for the ride ahead.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_56_10</DOCNO>
            	<TEXT> https://preview.redd.it/1mexbkfxdbu61.png?width=1293 amp;format=png amp;auto=webp amp;s=4f2fbeb70267a1f1bfa5c2fe1945557026e0ae15</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_57_0</DOCNO>
            	<TEXT>$ZOMD announcing Q4/2020 Year-End results today</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_58_0</DOCNO>
            	<TEXT>$MOXC (O2O/martech) was 21.73% in the green yesterday and is up 2.15% premkt</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_59_0</DOCNO>
            	<TEXT>Zoomd Q4/SaaS Analysis</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_59_1</DOCNO>
            	<TEXT> Started the morning by reviewing Zoomd's Q4/2020 financial results, one of my portfolios martech option ( [https://seekingalpha.com/pr/18278425-zoomd-reports-q4-and-year-end-2020-financial-results-and-provides-operational-update](https://seekingalpha.com/pr/18278425-zoomd-reports-q4-and-year-end-2020-financial-results-and-provides-operational-update)) I bought ZOMD ZMDTF shares a few months back, and its looking like 2021 is going to be a great year for these guys, with 30-40% projected revenue growth.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_59_2</DOCNO>
            	<TEXT>I wanted to take the chance to do a deep-dive on Zoomds SaaS platform, which for me is one of their most interesting services.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_59_3</DOCNO>
            	<TEXT>Zoomd's Intelligent Self-Serve SaaS Campaign Management Platform enables you to manage all your premium and social user acquisition campaigns in one place.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_59_4</DOCNO>
            	<TEXT>The platform offers a number of premium media channels to advertise on, including Facebook, TikTok, Instagram, Twitter, Snapchat, Twitter, Apple Search, and Google with each channel already incorporating built-in mechanisms to prevent ad fraud.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_59_5</DOCNO>
            	<TEXT>So now you can connect your current Facebook, Instagram, Google, Snapchat, Twitter, Apple Search and TikTok ad accounts on one platform.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_59_6</DOCNO>
            	<TEXT>The platform is driven by artificial intelligence (AI), machine learning, and prediction and automation technologies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_59_7</DOCNO>
            	<TEXT>Thus, Zoomds self-served, license-based, SaaS platform allows advertisers, both large and small, to easily and conveniently access, operate, and monitor all user acquisition campaigns themselves via a single dashboard while eliminating the need for advertisers to manage the campaign processes separately for each media channel, potentially saving both time and financial resources.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_59_8</DOCNO>
            	<TEXT>So now your company can convert all those management fees into media power-moves.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_59_9</DOCNO>
            	<TEXT>Check em out, Zoomds integrated SaaS platform just one factor that is giving me high hopes for big earnings robust growth in 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_59_10</DOCNO>
            	<TEXT>Sources: [https://seekingalpha.com/news/3673569-zoomd-launches-dsp-service-raises-fy21-revenue-projections](https://seekingalpha.com/news/3673569-zoomd-launches-dsp-service-raises-fy21-revenue-projections),[ https://www.prnewswire.com/il/news-releases/zoomd-launches-its-intelligent-self-serve-saas-campaign-management-platform-845425286.html](https://www.prnewswire.com/il/news-releases/zoomd-launches-its-intelligent-self-serve-saas-campaign-management-platform-845425286.html)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_60_0</DOCNO>
            	<TEXT>Zoomd Q4/SaaS Analysis</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_61_0</DOCNO>
            	<TEXT>CVSI and SPRWF are riding the bull tide today, up 5.99% and 5.23% respectively</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_62_0</DOCNO>
            	<TEXT>Buying the dip on $INNO premket, positive press overnight is gonna drive this CBD penny up during trading today</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_63_0</DOCNO>
            	<TEXT>$[IPOT.CN](https://IPOT.CN) is also up 22.45% atm, not sure whats going on there but bracing myself for a rollercoaster ride today</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_64_0</DOCNO>
            	<TEXT>ZSAN Correction Today?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_64_1</DOCNO>
            	<TEXT>Zosano Pharma (ZSAN) is a biotech firm that has been working on developing a transdermal microneedle treatment for migraines called Qtrypta.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_64_2</DOCNO>
            	<TEXT>As indicated by the spike and then correction in February 2021 (see chart below), ZSAN is no stranger to Reddit stonkers and the general volatility of both pennystock and the biotech sector.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_64_3</DOCNO>
            	<TEXT>That said, lets cut to the chase.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_64_4</DOCNO>
            	<TEXT>More or less YTD, ZSAN has been following a strong upward channel chart pattern.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_64_5</DOCNO>
            	<TEXT>Since early April, the stock has dipped slightly below a diagonal support, and has seen a particularly rocky week of trading, which makes sense given their listing on NASDAQ.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_64_6</DOCNO>
            	<TEXT>Fast forward to today, ZSAN is up 17.65% premarket.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_64_7</DOCNO>
            	<TEXT>Given the prevailing chart trend, I have a good feeling we're going to see either a correction or spike in ZSAN today, hopefully brining this biotech penny above its ascending support-cum-resistance.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_64_8</DOCNO>
            	<TEXT>Watching closely, good luck trading out their today ladies and gentlemen.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_64_9</DOCNO>
            	<TEXT>https://preview.redd.it/f353mmajspu61.png?width=1283 amp;format=png amp;auto=webp amp;s=2e67db7b002355d083afef59e3edab39340972da</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_65_0</DOCNO>
            	<TEXT>ZSAN Correction Today?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_66_0</DOCNO>
            	<TEXT>Half a Year After Trumps Defeat, Arizona Republicans Are Recounting the Vote</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_67_0</DOCNO>
            	<TEXT>Watching $ZMDTF closely for a reversal of momentum, got a feeling they'll punch through their $0.4 resistance this week</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_68_0</DOCNO>
            	<TEXT>I got in at $0.45, sitting and back and waiting for an afternoon spike, you're right re that AKMY trading volume keeps on climbing</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_69_0</DOCNO>
            	<TEXT>The display on Google/Yahoo finance is misleading, they just had their IPO today and the initial share price was $0.29.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_69_1</DOCNO>
            	<TEXT>Until other platforms get their act together, I'd recommend consulting the TSXV official page for accurate detes; [https://money.tmx.com/en/quote/AKMY](https://money.tmx.com/en/quote/AKMY); this shows that they're in fact up 34% today</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_70_0</DOCNO>
            	<TEXT>Ya for sure, its pretty confusing, hopefully tomorrow it'll be straightened out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_70_1</DOCNO>
            	<TEXT>Meanwhile happy trading!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_71_0</DOCNO>
            	<TEXT>$AKMY up 10% and climbing fast in what is only its 2cnd day trading as a public co on TSXV, recyclingtech startup with what looks a rock-solid paradigm and robust growth forecasts</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_72_0</DOCNO>
            	<TEXT>Its $AKMY/$AKMY.V</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_0</DOCNO>
            	<TEXT>Alkemy/K.B. Recycling (AKMY AKMY.V) Due Diligence</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_1</DOCNO>
            	<TEXT>**First things first, a bit about the company:** Alkemy (TSXV: AKMY) has developed a unique plastic recycling process for plastic bags and sheets that traditionally have been earmarked for the landfill, allowing this trash to mushroom into one of the largest pollutants in the world.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_2</DOCNO>
            	<TEXT>Addressing this global plastic crisis, Alkemy employs a dynamic one-step process that integrates both recycling and finished-product manufacturing within a single manufacturing pipeline, i.e. the "waste-to-product paradigm.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_3</DOCNO>
            	<TEXT>This revolutionary move has enabled Alkemy to reduce the cost of the recycled plastic as raw materials, while dramatically increasing its profit margin per metric ton. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_4</DOCNO>
            	<TEXT>Now for some DD:** Alkemy went public last week (4/28) on TSXV.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_5</DOCNO>
            	<TEXT>They had a very encouraging first week of trading, closing off the week at $0.60, +50% from its share price at Thursdays market close, and more than +100% its initial public offering of $0.29 a share.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_6</DOCNO>
            	<TEXT>Moreover, on both Wednesday and Thursday of last week it appears that AKMY was not yet registered on most trading platforms/brokerage services; the nearly 300% jump in trading volume on Friday (up to 2.7m) is reflective of this issues resolution.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_7</DOCNO>
            	<TEXT>Overall, these are all excellent indicators of future viability and investor confidence in this newly-public company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_8</DOCNO>
            	<TEXT>On Friday, Alkemy announced it had published its 2020 Financial Results, performed by an independent audit ([https://finance.yahoo.com/news/k-b-recycling-industries-ltd-203000141.html](https://finance.yahoo.com/news/k-b-recycling-industries-ltd-203000141.html), available on Sedar).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_9</DOCNO>
            	<TEXT>Though the company reported net losses for 2020, I believe a number of factors need to be born in mind when we consider these results: * The losses represent the outcome of $10m investment in developing one of the most disruptive technologies in the plastic recycling industry.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_10</DOCNO>
            	<TEXT>Alkemys founders have invested funds, much out-of-pocket, to test and ultimately demonstrate their POC; the fact that theyve since cornered 70% of the construction plastic market in Israel is a strong sign of how wildly successful their innovation truly is. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_11</DOCNO>
            	<TEXT>Another reason explaining the 2020 losses is that until now, Alkemy has been in the POC stage.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_12</DOCNO>
            	<TEXT>After proving that their tech works, theyve since gone public and inked deals with EU power-house economies like France and Germany.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_13</DOCNO>
            	<TEXT>This means that Alkemy is only just getting started; after proving the profitability of their approach, theyre now taking the paradigm global. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_14</DOCNO>
            	<TEXT>The economic disruptions and nationally-imposed lockdowns (esp.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_15</DOCNO>
            	<TEXT>in Israel, where Alkemy is based) in 2020 as a result of COVID-19 likely exercised a negative impact on year-end results.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_16</DOCNO>
            	<TEXT>Though Alkemy aggressively adapted to new market circumstances, it was a tough time for startups across the board. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_17</DOCNO>
            	<TEXT>With a 50% profit margin, Alkemy is recycling plastics at nearly 300% the market standard of \~15%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_18</DOCNO>
            	<TEXT>This means that Alkemy is trail-blazing uncharted terrain with no serious competitors in sight.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_19</DOCNO>
            	<TEXT>Combine this with the nearly unlimited amount of dirty plastics they can use as inputs, and Alkemys position vis-a-vis the industry as a whole appears even more positive.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_20</DOCNO>
            	<TEXT>To sum things up, my two-cents is that Alkemys 2020 Financials are reflective of a truly ground-breaking startup making the transition from its POC to being a publicly-traded company with global aspirations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_21</DOCNO>
            	<TEXT>Its IPO coincides with an uptick in attention being devoted to sustainable industry, meaning AKMY is a green ticker to get excited about.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_22</DOCNO>
            	<TEXT>The results of their POC, not to mention the bullishness shown by investors last week, marks Alkemy out as a green pennystock to keep a close eye on.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_73_23</DOCNO>
            	<TEXT>https://preview.redd.it/0ec6hp0q1pw61.png?width=1238 amp;format=png amp;auto=webp amp;s=85c7d30c679b8d32e04891ba231b464b77bab499</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_74_0</DOCNO>
            	<TEXT>Alkemy/K.B. Recycling (AKMY AKMY.V) Due Diligence</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_75_0</DOCNO>
            	<TEXT>Alkemy/K.B. Recycling (AKMY AKMY.V) Due Diligence</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_76_0</DOCNO>
            	<TEXT>Alkemy/K.B. Recycling (AKMY AKMY.V) Due Diligence</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_77_0</DOCNO>
            	<TEXT>Hopefully the EU is better about pursuing its emissions targets than its been with the continent's vaccine rollout...I for one am not overly-optimistic regarding Brussel's ability to implement such far-reach legislation, but lets see</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_78_0</DOCNO>
            	<TEXT>Alkemy/K.B. Recycling (AKMY AKMY.V) Due Diligence</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_79_0</DOCNO>
            	<TEXT>Think you might be looking at an outdated version, try this: [https://www.alkemy.solutions/](https://www.alkemy.solutions/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_80_0</DOCNO>
            	<TEXT>Consult the Prospectus that's up on Sedar (April 1, pg.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_80_1</DOCNO>
            	<TEXT>2, under K.B. Recycling).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_80_2</DOCNO>
            	<TEXT>Ordinary shares were offered to the public at $0.29; the jump up to $0.73 was likely due to day traders inflating the price and then dumping via premarket buys on its first day trading</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_81_0</DOCNO>
            	<TEXT>From what I understand, their plan is to build new factories atop plastic landfills and dumping sites, thereby effectively eliminating transport/fuel/logistics costs while providing them with mountains of dirty plastics for use as "raw materials."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_81_1</DOCNO>
            	<TEXT>I'm with you about this company's potential in closing the loop on plastic, I too am watching for more updates!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_82_0</DOCNO>
            	<TEXT>TSX and TSXV are getting pummeled along with the rest of the market, but for anyone that's been sleeping on $AKMY over the past few days, now is a perfect entry point for the long-haul</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_83_0</DOCNO>
            	<TEXT>CWBHF and BLOZF were some of my only tickers to close in the green yesterday (+2.68% and +1.88%, respectively).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_83_1</DOCNO>
            	<TEXT>Meanwhile INNO in a dip, prime entry point on a CBD/pharma hybrid ticker</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_84_0</DOCNO>
            	<TEXT>Perfect time to rip the dip in AKMY, newby pennystock that got dragged down by the market yesterday but is itching for an upward break</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_85_0</DOCNO>
            	<TEXT>Loaded up on a bit of ELCR after it was +900% yesterday, hoping for some fun day trading with this hot penny</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_86_0</DOCNO>
            	<TEXT>[https://www.newswire.ca/news-releases/renah-persofsky-icd-d-joins-alkemy-board-of-directors-893601660.html](https://www.newswire.ca/news-releases/renah-persofsky-icd-d-joins-alkemy-board-of-directors-893601660.html) Looks like ya timed that well, AKMY announcing a great new addition to their board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_86_1</DOCNO>
            	<TEXT>Now wait for the rise ;)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_87_0</DOCNO>
            	<TEXT>Just found INNPF, they're newly available after an OTC uplisting.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_87_1</DOCNO>
            	<TEXT>CBD power penny that's +300% since last fall...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_0</DOCNO>
            	<TEXT>Innocan (INNPF): A Hidden OTC Gem</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_1</DOCNO>
            	<TEXT>Innocan (CSE:INNO, OTCQB:INNPF) is emerging as one of my small/micro cap portfolios most robust and profitable stocks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_2</DOCNO>
            	<TEXT>I first noticed INNO back in June 2020 when it was at $0.16, and since, my initial investment has nearly tripled in less than a year (closed at $0.46 Friday after a tough week).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_3</DOCNO>
            	<TEXT>Overall, INNO is +10% over the past 3 months, +73% over the past 6mo, and up a whopping 109% in the past 12 months from today; doesnt get much better than that.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_4</DOCNO>
            	<TEXT>Now onto some DD and why I think Innocans OTC ticker is a hidden gem waiting for some action.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_5</DOCNO>
            	<TEXT>The reason I initially went in on Innocan is that I get the impression they are filling a much-needed niche in creating science-driven CBD delivery platforms and solutions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_6</DOCNO>
            	<TEXT>As North American markets get ever hotter for all things cannabis and CBD, the high number of smaller companies currently competing for space in a crowded field is bound to narrow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_7</DOCNO>
            	<TEXT>I for one have singled out Innocan as a clear winner; these guys are making a lucrative niche for themselves at the intersection of CBD and pharma, and have the scientific credentials to distinguish themselves from your average pot stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_8</DOCNO>
            	<TEXT>A few weeks ago, I read that Innocans OTC ticker uplisted from Pink to OTCQB, and as part of the transition gained DTC eligibility in the process.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_9</DOCNO>
            	<TEXT>In short, this is awesome news.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_10</DOCNO>
            	<TEXT>Here are some thoughts on what this means for the company and its OTC ticker (INNPF): * DTC eligibility translates into increased liquidity for the firm, the ability to broaden their shareholder base, and an overall stronger presence within the US market. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_11</DOCNO>
            	<TEXT>Uplisting from Pink to OTCQB is a strong indicator that Innocan enjoys a high level of compliance with American regulatory bodies and maintains proper financial transparency.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_12</DOCNO>
            	<TEXT>For me, this simply makes investing in Innocan a far less risky venture. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_13</DOCNO>
            	<TEXT>There are a number of practical benefits to an OTCQB listing over Pink, such as INNPFs availability on a far wider range of brokerage platforms, access to more sophisticated and efficient technology, as well as the implicit assurance to investors that Innocan is keeping its books and house in order.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_14</DOCNO>
            	<TEXT>Given what Ive seen from Innocan over the course of the past year, this company is on course for significant long-term growth.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_15</DOCNO>
            	<TEXT>Theyve recently announced a whole slew of new additions to their scientific advisory board, global distribution agreements, and promising results from ongoing trials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_16</DOCNO>
            	<TEXT>This little bit of due diligence is NOT financial advice or counsel, purely personal opinion. (</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_88_17</DOCNO>
            	<TEXT>Position: 5000 INNO @ 0.16, 2500 INNPF 0.38) said, Ill be waiting for a good in to load up on some INNPF for my microcap portfolio.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_89_0</DOCNO>
            	<TEXT>Innocan (INNPF): A Hidden OTC Gem</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_90_0</DOCNO>
            	<TEXT>Innocan (INNPF): A Hidden OTC Gem</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_91_0</DOCNO>
            	<TEXT>I'm in the same boat, that's why I was so relieved these guys got uplisted to OTCQB!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_92_0</DOCNO>
            	<TEXT>Its all about the long term potential I see in these guys, check in with me in a few months and we'll see where things stand compadre</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_93_0</DOCNO>
            	<TEXT>Good thing INNPF just uplisted to OTCQB from Pink, otherwise I'd be in in trouble</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_0</DOCNO>
            	<TEXT>JustKitchens (JK.V) Global Expansion Strategy DD/Prospects</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_1</DOCNO>
            	<TEXT>One of the more interesting innovations embraced by the global food/restaurant industry in response to COVID-related lockdowns are ghost kitchens.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_2</DOCNO>
            	<TEXT>Particularly in the context of dense urban areas with correspondingly high real estate prices, ghost kitchens are fast-evolving as a more efficient alternative to standard brick-and-mortar establishments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_3</DOCNO>
            	<TEXT>Though the whole ghost kitchen paradigm is dynamic and relatively new, a variety of different firms are beginning to enter this growing niche.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_4</DOCNO>
            	<TEXT>Some mega-food companies like McDonalds (MCD), Chipotle (CMG), and Dennys (DENN) are trying to incorporate ghost kitchens in their portfolio of services, while a new set of smaller, dedicated ghost kitchen-specific firms are beginning to list on major capital markets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_5</DOCNO>
            	<TEXT>I wanted to take the chance to do some DD on an up-and-coming ghost kitchen player, JustKitchen (JK.V), which just listed on the TSX Venture exchange back in April 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_6</DOCNO>
            	<TEXT>First a bit about the company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_7</DOCNO>
            	<TEXT>JustKitchen is primarily an operator of ghost kitchens specializing in the development and marketing of proprietary and franchised delivery-only food brands for customers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_8</DOCNO>
            	<TEXT>JustKitchen uniquely utilizes a hub-and-spoke operating model (with proven a revenue stream of $50m/hub), which features advanced food preparation taking place at larger hub kitchens and final meal preparation taking place at smaller spoke kitchens located in areas with higher population densities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_9</DOCNO>
            	<TEXT>Justkitchen has shown sizable growth in the past year, and is expected to continue this trend considering its strategy to expand in all the mentioned locations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_10</DOCNO>
            	<TEXT>Expected profits from each hub are estimated around $5 million, meaning that if JK continues apace with its expansion plan, this firm will be rolling in profits by year-end.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_11</DOCNO>
            	<TEXT>JustKitchen hails from Taiwan, and they have been pursuing an aggressive program of expansion in recent months.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_12</DOCNO>
            	<TEXT>JustKitchens rapid growth illustrates the degree to which its gradually becoming the new cloud kitchen of Asia, and it plans to open new locations in the United States, Canada, Philippines, and Singapore over the next two years. (</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_13</DOCNO>
            	<TEXT>Do the math, and this translates into $200m revenue, which is very significant for a firm that has a $85m market-cap) In this vein, a few weeks ago Justkitchen opened a new ghost kitchen in the world famous Taipei 101 skyscraper (basically the Empire State Building of Taiwan).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_14</DOCNO>
            	<TEXT>Every day, Taipei 101 is a destination where more than 10,000 people work in the building, and there are more than 5,000 visitors shopping at the connected mall and visiting its observation deck.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_15</DOCNO>
            	<TEXT>The opening occurred on pace with the Company's projection to have 22 ghost kitchen locations operating across Taiwan by the end of the calendar year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_16</DOCNO>
            	<TEXT>Internationally, JustKitchen is focusing on key cities on the west coast in the United States as a plan of expansion for the remainder of this year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_17</DOCNO>
            	<TEXT>The strategy anticipates the deployment of both in-house and partner brands, with its proprietary technology and operational expertise, all adapted to leverage local vendors, through established supply chains, to customers with known demographics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_18</DOCNO>
            	<TEXT>Their approach in the Philippines (a sizable national market of 110m mouths) is expected to closely resemble its hub-and-spoke operating model in Taiwan, since the countrys cost structure and population density are somewhat similar.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_19</DOCNO>
            	<TEXT>As for Singapore, JustKitchens entry is expected to resemble the same approach for Hong Kong given these two cities astronomical real-estate prices and dense urban populations, both critical factors in determining the economic viability of ghost-kitchens in a given locale. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_20</DOCNO>
            	<TEXT>Given JustKitchens performance in recent months and ambitious plans for 2021, I see this Canadian penny stock as a golden investment opportunity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_21</DOCNO>
            	<TEXT>Since their initial listing on TSXV on April 15 theyre up 13% already, which is a robust indicator for steady growth down the road.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_22</DOCNO>
            	<TEXT>Internally, they seem to have an experienced management team with good contacts across both East Asian and Western capital markets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_23</DOCNO>
            	<TEXT>Ill be watching closely to see how JK.V performs in relation to the food-industry movers (MCD, DENN, and CMG), but meanwhile Im very optimistic on JKs projected growth through the remainder of 2021.**</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_94_24</DOCNO>
            	<TEXT>\[This DD represents my personal views only and its not financial advice\] https://preview.redd.it/v3ist1my3a271.png?width=1062 amp;format=png amp;auto=webp amp;s=d6ceb1f6c59b5a9f17ad433e6907ddf33f801dbe</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_95_0</DOCNO>
            	<TEXT>JustKitchens (JK.V) Global Expansion Strategy DD/Prospects</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_96_0</DOCNO>
            	<TEXT>JustKitchens (JK.V) Global Expansion Strategy DD/Prospects</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_97_0</DOCNO>
            	<TEXT>JustKitchens (JK.V) Global Expansion Strategy DD/Prospects</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_98_0</DOCNO>
            	<TEXT>Got a bad feeling about COIN, looks like crypto investors are suddenly feeling super shaky, may add more volatility to what's already the Wild West of Forex.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_98_1</DOCNO>
            	<TEXT>Other feeling bullish on PLTR and TSLA</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_99_0</DOCNO>
            	<TEXT>Great resource, thanks for the share!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_100_0</DOCNO>
            	<TEXT>I agree regarding the hub and spoke idea, that's the primary reason I feel these guys are in a solid position to successfully implement their global expansion plan</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_101_0</DOCNO>
            	<TEXT>Else Nutrition also announced 90% revenue growth from Q4 2020 to Q1 2021, both its tickers (BABY and BABYF) are in the green and trading at nice volumes today</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_0</DOCNO>
            	<TEXT>Else Nutrition Rides the Plant-Based Baby Mega-Trend (DD)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_1</DOCNO>
            	<TEXT>The reset of global markets following the 2020 COID-induced dip has sparked a number of profound changes in consumption patterns, especially within the food sector.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_2</DOCNO>
            	<TEXT>As issues such as climate action, land use, and diet are re-centered, a great deal of attention is being directed to plant-based and vegan food alternatives.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_3</DOCNO>
            	<TEXT>Some of these trends include various brands ditching plastic, carbon labeling, vegan innovation, and regenerative agriculture.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_4</DOCNO>
            	<TEXT>Given this fundamental change in food consumption, I wanted to take the time to do a little DD on this exciting trend and some of its leading proponents.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_5</DOCNO>
            	<TEXT>For example, vegans and vegetarians have been making chicken substitutes for many years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_6</DOCNO>
            	<TEXT>This year saw some new pre-made, easy-to-work-with protein products that potentially make real chicken a thing of the past.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_7</DOCNO>
            	<TEXT>For instance, Daring Foods (private) recently released their 100% plant-based chicken pieces.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_8</DOCNO>
            	<TEXT>This year we are expecting to see more development of fish alternatives, some brands have already been in the works such as Good Catch and Sophies Kitchen with their fishless tuna.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_9</DOCNO>
            	<TEXT>For many years, we have already seen alternative milks such as almond, soy, rice, and even oat.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_10</DOCNO>
            	<TEXT>Yet, recently the plant-based milk category has boomed, offering a wider range of alternative milks than before.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_11</DOCNO>
            	<TEXT>Even though many of these alternatives may seem healthy due to its nature of being plant-based, some include unhealthy additives like oils, sugars, and salt additives.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_12</DOCNO>
            	<TEXT>Brands such as Oatly have been viewed as unhealthy alternatives or just as equal to dairy milk.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_13</DOCNO>
            	<TEXT>Consumers have found that some of these oat milk brands contain maltose, which are more refined carbohydrates, and are worse for you than complex carbs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_14</DOCNO>
            	<TEXT>This causes a rise in blood glucose and insulin levels.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_15</DOCNO>
            	<TEXT>Though, some brands have taken the extra mile to make plant-based products healthier One firm I feel is aggressively driving the plant-based food market is Else Nutrition.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_16</DOCNO>
            	<TEXT>Else Nutritions revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_17</DOCNO>
            	<TEXT>It caters products to the infant, toddler, children, and adult markets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_18</DOCNO>
            	<TEXT>Else Nutrition has successfully developed a baby and toddler formula which recently ranked #1 top seller in its category on Amazon AMZN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_19</DOCNO>
            	<TEXT>Their mission is to better serve children with allergies, intolerances and dietary restrictions as well as families who seek plant-based clean nutrition for their babies and toddlers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_20</DOCNO>
            	<TEXT>This company is publicly traded and listed as TSX Venture under the trading symbol BABY.V, in addition to its OTCQX ticker BABYF.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_21</DOCNO>
            	<TEXT>So far, the company has successfully launched its brand on three online platforms, namely Thrive Market, iHerb, and PlantX. The company plans to begin distribution with Salt Lake City-based Associated Food Stores (AFS).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_22</DOCNO>
            	<TEXT>AFS is a large retail company, both food and non-food goods, with 1,400 employees and annual revenue of $1.6B. Else's Plant-Based Complete Nutrition for Toddlers will soon be available in an initial 32 locations, with KeHe to deploy product up to 300 additional independent grocers in the near future.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_23</DOCNO>
            	<TEXT>Based on Else Nutritions latest earnings release for Q4 of 2020, the company reported a quarterly revenue of $598K and GAAP net loss of $14.03 million.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_24</DOCNO>
            	<TEXT>In comparison, last year the company earned revenue of $254.2K and had a GAAP net loss of $968.4K. Else Nutrition Holdings Inc. has recently reported their Q1 financials, reporting revenues of C$1,135 thousand, an 90% growth over revenues of C$598 thousand in Q4 2020 and an increase of 282% vs. revenues over C$297 thousand in Q1 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_25</DOCNO>
            	<TEXT>149% growth in quarter-over-quarter Formula revenues of C$862 thousand in Q1 2021 over C$346 thousand in Q4 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_26</DOCNO>
            	<TEXT>With such a growing trend in plant-based foods, many brands are taking the opportunity to excel in the industry and promote their products to as many consumers as possible.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_27</DOCNO>
            	<TEXT>The world is slowly but surely moving towards a direction that is more sustainable, progressive, and eco-friendly.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_28</DOCNO>
            	<TEXT>Given its performance since its IPO, Else Nutrition Holdings Inc. has immense potential to succeed and become one of the most known brands around the world in the next few years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_102_29</DOCNO>
            	<TEXT> https://preview.redd.it/gkk3o7ve4o371.png?width=1069 amp;format=png amp;auto=webp amp;s=61ff88363d967cf83df94c63d3e3e27ecbd2beb9</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_103_0</DOCNO>
            	<TEXT>Else Nutrition Rides the Plant-Based Baby Mega-Trend (DD)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_104_0</DOCNO>
            	<TEXT>Else Nutrition Rides the Plant-Based Baby Mega-Trend (DD)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_0</DOCNO>
            	<TEXT>CleanTech Innovator Alkemy (TSXV:AKMY) is Building a Dream Team for Ambitious Upscaling</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_1</DOCNO>
            	<TEXT>The redirection of global attention and resources to combating the climate crisis is creating a warm investment climate for greentech and cleantech innovators across the world.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_2</DOCNO>
            	<TEXT>TSX/TSXV is a pretty cool exchange for a number of budding climate-tech companies like SolarVest BioEnergy (SVS), ClearFord Water Systems (CLI) and Eguana Technologies (EGT); check out this link for some more TSX cleantech tickers to keep an eye on: [https://investingnews.com/daily/tech-investing/cleantech-investing/top-canadian-cleantech-stocks/](https://investingnews.com/daily/tech-investing/cleantech-investing/top-canadian-cleantech-stocks/) Another such firm, Alkemy (AKMY) went public on TSXV at the end of April.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_3</DOCNO>
            	<TEXT>For starters, K.B. Recycling Industries (conducting business as Alkemy) is an innovative plastics recycling company that developed a unique plastic recycling process for plastic bags and sheets traditionally not considered economically viable for recycling.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_4</DOCNO>
            	<TEXT>For recent financials/NRs on AKMY see: [https://www.alkemy.solutions/investors/investors-financials](https://www.alkemy.solutions/investors/investors-financials) In the past few weeks we've witnessed new recruitments to the board of directors with the ultimate intention of taking Alkemy a step forward in its expansion blueprint.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_5</DOCNO>
            	<TEXT>As Alkemy's CEO stated:  gt;"As we aim to enter global partnerships for the deployment of Alkemy recycling plants, we are building a strong board of best-of-class directors to help guide us through our growth stage and the entailed logistics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_6</DOCNO>
            	<TEXT>In May, Leon Koffler joined Alkemy's board of directors ([https://finance.yahoo.com/news/leon-koffler-joins-alkemy-board-150700120.html](https://finance.yahoo.com/news/leon-koffler-joins-alkemy-board-150700120.html)).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_7</DOCNO>
            	<TEXT>Mr. Koffler is one of the most prominent global businessmen and industrialists in Israel.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_8</DOCNO>
            	<TEXT>Born in Canada, Mr Koffler is the owner and Chairman of Israel's leading drugstore chain with over 230 stores throughout Israel and many more worldwide.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_9</DOCNO>
            	<TEXT>In other words, Koffler is a proven management wizard and successful entrepreneur that has a lot to contribute to an up-and-coming firm like Alkemy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_10</DOCNO>
            	<TEXT>In a similar vein, on June 8, Alkemy appointed Noah Hershcoviz for its Board of Directors ([https://finance.yahoo.com/news/alkemy-appoints-noah-hershcoviz-board-182800933.html](https://finance.yahoo.com/news/alkemy-appoints-noah-hershcoviz-board-182800933.html)).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_11</DOCNO>
            	<TEXT>Mr. Hershcoviz is a capital market specialist with a successful track record leading and executing strategic transformation projects and complex transactions with over 12 years of experience with fast-growing companies and executing roles improving operational performance.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_12</DOCNO>
            	<TEXT>He Co-founded ALabs Finance  amp; advisory, is a CPA and attorney of law, holds a BA and LLB.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_13</DOCNO>
            	<TEXT>The nomination of Mr. Hershcoviz is to support Alkemy's M amp;A strategy, investor relations approach and corporate governance.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_14</DOCNO>
            	<TEXT>Due to the recent announcements about grade-A corporate personnel additions to the company, it is clear that Alkemy had been up and running preparing for their planned up scaling and global expansion. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_15</DOCNO>
            	<TEXT>These are highly strategic human capital acquisitions for AKMY at this early stage; if this firm can begin proceeding with its construction of mega-recycling plants in key markets such as Canada, the US, and the EU, this firm will be rolling in cash as it capitalizes on 1) the anti-plastic megatrend, and 2) its pioneering recycling process that is far more profitable than the industry standard.**</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_16</DOCNO>
            	<TEXT>Alkemy is a new player to TSXV, but I see these guys doing incredible things in the years to come.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_17</DOCNO>
            	<TEXT>Meanwhile, Ill be watching closely for more developments and updates moving forward.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_105_18</DOCNO>
            	<TEXT>\[Disclaimer: this DD represents a personal opinion and does not constitute financial advice\].</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_106_0</DOCNO>
            	<TEXT>CleanTech Innovator Alkemy (TSXV:AKMY) is Building a Dream Team for Ambitious Upscaling</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_0</DOCNO>
            	<TEXT>Innocan Pharma: A Bullish CBD Ticker with a Scientific Edge</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_1</DOCNO>
            	<TEXT>Cannabis legalization is sweeping over North America 16 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_2</DOCNO>
            	<TEXT>Investors remain enthusiastic about weeds future despite all the ups and downs the global industry has experienced in recent years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_3</DOCNO>
            	<TEXT>When it comes to marijuana investments, Ive always been partial to those companies whose business strategy goes well beyond the bud into other products such as cosmetic and therapeutic products.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_4</DOCNO>
            	<TEXT>In that vein, one firm in particular stands out from the rest--Innocan Pharma.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_5</DOCNO>
            	<TEXT>First off, Innocan stock (CSE: INNO) (OTCQB: INNPF) (FSE: IP4) has witnessed incredibly aggressive growth over recent years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_6</DOCNO>
            	<TEXT>To date, INNO (CSE) is +38.8%YTD and up a whopping 232% over the past year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_7</DOCNO>
            	<TEXT>Their OTC ticker, INNPF, is also +14% YTD and +76.7% over the past year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_8</DOCNO>
            	<TEXT>In a year that has witnessed its fair share of ups and downs for the cannabis sector, these metrics alone single out Innocan as a hot option.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_9</DOCNO>
            	<TEXT>But lets dig a bit deeper; what really distinguishes Innocan as a potential big-winner for your cannabis portfolio is its intensive R amp;D efforts and overall progress in pioneering the science of cannabis.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_10</DOCNO>
            	<TEXT>InnoCan Pharma's scientific approach to CBD is once again proving the immense potential of cannabinoid applications in the broader pharma/biotech industry.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_11</DOCNO>
            	<TEXT>In the past two weeks we've witnessed some successful results from Innocans ongoing clinical studies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_12</DOCNO>
            	<TEXT>The wave of good press started with their innovative liposome platform technology that displayed a 7-week presence of CBD in the bloodstream, compared to the 24-hour duration when administered traditionally.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_13</DOCNO>
            	<TEXT>This significantly prolonged release of CBD into the bloodstream translates into meaningful uses for long-term treatments, inflammation reduction, and more.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_14</DOCNO>
            	<TEXT>The second encouraging article that came out focused on the clinical study that has validated Innocans CBD eye serum as an anti-puffiness solution.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_15</DOCNO>
            	<TEXT>This innovative product had proved a positive anti-puffiness effect after 28 days of use; roughly 54% of participants of the study showed a decrease of volume of the participants' eye bags of around 52.18% and with a maximum decrease observed of 90.06%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_16</DOCNO>
            	<TEXT>Last but not least is the CBD Integrated Anti-Aging Sleeping Mask that induces a reduction in the visibility of facial skin wrinkles.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_17</DOCNO>
            	<TEXT>The study showed that women who used the product for a period of four weeks experienced a reduction in the appearance of their lines and wrinkles by as much as 28.8%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_18</DOCNO>
            	<TEXT>The results were extremely positive, and 90.5% of the participants expressed that they would recommend the product to a friend and would like to buy the product.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_19</DOCNO>
            	<TEXT>What makes Innocan stand out is the ability to measure the true effect of its CBD solutions via objective, scientific trials rather than being based on self-assessment or self-report as is common across the industry as a whole.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_20</DOCNO>
            	<TEXT>In my opinion, these promising catalysts are just the beginning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_21</DOCNO>
            	<TEXT>InnoCan Pharma is a well-oiled CBD machine whose science-driven product line holds enormous potential for European, North American, and Israeli markets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_107_22</DOCNO>
            	<TEXT>https://preview.redd.it/n0j7c1bi5t771.png?width=1063 amp;format=png amp;auto=webp amp;s=6f4d9e2f99f1a53af6f0e9101ca4385c6623c048</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_108_0</DOCNO>
            	<TEXT>Innocan Pharma: A Bullish CBD Ticker with a Scientific Edge</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_109_0</DOCNO>
            	<TEXT>INNPF +37% for an ATH, I think we just kissed the man on the moon goodbye folks</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_0</DOCNO>
            	<TEXT>Innovative BioTech Firm Bonus (BONS.TA) Expands from Bone Therapy to COVID Treatments</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_1</DOCNO>
            	<TEXT>So Ive been working to expand my biotech portfolio beyond my trusty American/Canadian tickers to other cool and innovative capital markets across the globe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_2</DOCNO>
            	<TEXT>The Tel Aviv Stock Exchange (TASE) is home to a number of innovative firms, especially in the subsector of regenerative medicine and cell therapy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_3</DOCNO>
            	<TEXT>One firm--Bonus Biogroup (BONS.TA)--caught my attention during a crazy spike in trade volume today (nearly 4m, compared to its avg 540k).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_4</DOCNO>
            	<TEXT>Outliers like this are worth a closer look, so here we go.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_5</DOCNO>
            	<TEXT>Bonus has had an exciting year on TASE; theyre up 150% YTD and +200% over the past 12mo.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_6</DOCNO>
            	<TEXT>In short, thats some serious gains.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_7</DOCNO>
            	<TEXT>Zooming out a bit, The regenerative medicine market is expected to grow at a CAGR of over 30% during the period 20202026.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_8</DOCNO>
            	<TEXT>Combine that with strong BUY ratings from legit analysts (I consulted TradingView) and Id say that Bonus is an incredibly bullish, long-term investment opportunity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_9</DOCNO>
            	<TEXT>So what do these guys do?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_10</DOCNO>
            	<TEXT>BONS.TA has been working in cellular medicine and tissue engineering for years at this point in search of a solution for the regeneration and construction of bone tissue.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_11</DOCNO>
            	<TEXT>The central building block used to produce a living bone graft is mesenchymal cells, which are extracted from the patient's adipose tissue (type of connective tissue).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_12</DOCNO>
            	<TEXT>Alongside their efficacy in bone-tissue regeneration, mesenchymal cells can be used to reduce inflammation in the body caused by respiratory infections and cytokine-associated inflammatory processes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_13</DOCNO>
            	<TEXT>In addition to their ground-breaking bone tissue therapy (yes, these guys are literally growing bone cells and injecting them into patients with a specially-patented syringe), Bonus has been branching out to explore innovative therapeutic solutions to COVID.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_14</DOCNO>
            	<TEXT>Back in late May, they announced a 100% success rate in Phase-I clinical trials for their MesenCure drug, which works to decrease the cytokine storm that is behind some of the virus most grizzly systemic complications.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_15</DOCNO>
            	<TEXT>As COVID variants are bringing the efficacy of both vaccines and public health measures into question, this regenerative approach to treating the virus could be literally world-changing and life-saving.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_16</DOCNO>
            	<TEXT>In a nutshell, Im pretty impressed by the looks of this company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_17</DOCNO>
            	<TEXT>Ive got a few more Israeli biotech/cell therapy tickers lined up that I plan on doing further DD for when I have the chance (e.g PSTI.TA, BLRX.TA, ICCM.TA).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_18</DOCNO>
            	<TEXT>Meanwhile, Im enjoying expanding the horizons of my portfolio and personal knowledge in the field.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_110_19</DOCNO>
            	<TEXT>\[btw, Im not your financial advisor\]  https://preview.redd.it/58o4zj672t971.png?width=1050 amp;format=png amp;auto=webp amp;s=8e21de67ba1bf22c8fc75347eea16a0c5e0cc9d5</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_111_0</DOCNO>
            	<TEXT>Why the meme stock revolution will last</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_0</DOCNO>
            	<TEXT>The Race for NextGen COVID-19 Treatments: A Tale of Three BioTickers</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_1</DOCNO>
            	<TEXT>Following my previous DD on Bonus BioGroup (BONS.TA) and their success in stage I of the MesenCure COVID treatment Ive decided to dig a little deeper into some Israeli biotech/cell therapy tickers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_2</DOCNO>
            	<TEXT>I already noted here that the Tel Aviv Stock Exchange (TASE) seems to host a fairly large number of regenerative medicine and cell therapy firms, but I recently spotted two additional companies since my recent piece on BONS that are workingto engineer nextGen COVID therapies and solutions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_3</DOCNO>
            	<TEXT>You may wonder why I even bother looking into the COVID treatment market with the pandemic "seemingly" coming to an end.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_4</DOCNO>
            	<TEXT>Well, my first response is that its not over yet.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_5</DOCNO>
            	<TEXT>With the rapid expansion of the Delta variant and others, we are seeing a new rise in COVID cases in many countries around the world (Australia and India, to name a few) as well as an increased number of re-infection and vaccine resistance.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_6</DOCNO>
            	<TEXT>At the same time, the global COVID-19 treatment market is estimated to continue growing through 2020-2027 with high government spending on R amp;D and treatment development ([https://www.acumenresearchandconsulting.com/covid-19-treatment-market](https://www.acumenresearchandconsulting.com/covid-19-treatment-market)).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_7</DOCNO>
            	<TEXT>According to additional research, even after well reach herd immunity, COVID is likely to stay around in the form of an endemic disease affecting 10% of the world population every year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_8</DOCNO>
            	<TEXT>Bearing these predictions in mind, here are three Israeli BioTech firms worth keeping an eye on for those of you considering expanding your portfolios to some foreign capital markets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_9</DOCNO>
            	<TEXT>Pluristem Therapeutics (PSTI.TA)** Pluristem is a clinical-stage regenerative cell company developing cell therapies for conditions such as inflammation, muscle injuries, haematological disorders and radiation exposure.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_10</DOCNO>
            	<TEXT>The company has been conducting clinical trials treating Acute Respiratory Distress Syndrome (ARDS) associated with COVID using its PLX cell product, extracted from placentas.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_11</DOCNO>
            	<TEXT>It recently announced the end of stage II of their clinical trial and their move to the clinical readout to investigate the safety and efficacy of Pluristems PLX cells treatment. ([</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_12</DOCNO>
            	<TEXT>https://finance.yahoo.com/news/pluristem-brings-ards-associated-covid-111000797.html](https://finance.yahoo.com/news/pluristem-brings-ards-associated-covid-111000797.html)) **2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_13</DOCNO>
            	<TEXT>Enlivex Therapeutics (ENLV.TA)** Enlivex is a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumours.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_14</DOCNO>
            	<TEXT>In February, Enlivex reported positive results from its phase II clinical trial of the Allocetra COVID treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_15</DOCNO>
            	<TEXT>With a 90% success rate in stage II of the trial, Allocetra has been marked as a potential treatment for cytokine storm and organ dysfunctions linked to COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_16</DOCNO>
            	<TEXT>While the results seem promising, since February Enlivex has not released significant news regarding the COVID treatment trial and its stock has seen a sharp decline YTD. ([</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_17</DOCNO>
            	<TEXT>https://finance.yahoo.com/news/enlivex-reports-positive-top-line-125500981.htl](https://finance.yahoo.com/news/enlivex-reports-positive-top-line-125500981.htl)) **3.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_18</DOCNO>
            	<TEXT>Bonus BioGroup (BONS.TA)** Bonus BioGroup is a cellular medicine and tissue engineering firm developing solutions for the regeneration and construction of bone tissue.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_19</DOCNO>
            	<TEXT>Bonus utilizes extracted mesenchymal cells extracted from patients connective tissues from bone tissue therapy (aka, to grow and inject bone cells).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_20</DOCNO>
            	<TEXT>With COVID hitting, Bonus began exploring innovative therapeutic solutions using mesenchymal cells to decrease the cytokine storm caused by the virus.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_21</DOCNO>
            	<TEXT>Last week, Bonus announced a 100% success rate in the first phase of its clinical trials with a significant improvement in patients treated with its MesenCure therapy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_22</DOCNO>
            	<TEXT>They are now moving to phase II of the trial, expected to last approx.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_23</DOCNO>
            	<TEXT>30-60 days.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_24</DOCNO>
            	<TEXT>In addition, Bonus announced that MesenCure is a potential treatment for lung and tissue diseases also unrelated to COVID, thus increasing the potential value of its product. ([</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_25</DOCNO>
            	<TEXT>https://en.globes.co.il/en/article-israeli-co-bonus-biogroup-reports-covid-19-treatment-success-1001377650](https://en.globes.co.il/en/article-israeli-co-bonus-biogroup-reports-covid-19-treatment-success-1001377650)) While all three firms seem to perform well in their trials, their stocks have performed awfully darn differently in recent months (check out the chart below).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_26</DOCNO>
            	<TEXT>For starters, BONS is up a whammin 153.31% YTD, while ENLV is 6.48% in the red.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_27</DOCNO>
            	<TEXT>Meanwhile, PSTI slumped 46.43%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_28</DOCNO>
            	<TEXT>Likewise, the timing of recent NRs shows that BONS.TA is riding a surge of popular momentum (check the trade volume last Thursday, was like 5x the avg).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_29</DOCNO>
            	<TEXT>Combine that hype with the recent article (Globes, see link above) that seems to indicate Bonus is making serious forward progress in recent and ongoing clinical trials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_30</DOCNO>
            	<TEXT>So lets up wrap this little compare-contrast of cool cell therapy/biotickers trading on TASE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_31</DOCNO>
            	<TEXT>From the looks of it, 2021 has been a tough year for ENLV and PSTI, while BONS.TA seems to be surging due to recent advances in disruptive field of bone grafts and COVID treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_32</DOCNO>
            	<TEXT>Israeli BioTech firms are offering some interesting therapeutic solutions and investment possibilities, but also require deeper analysis/risk assessment/viability for your portfolio than your average American ticker.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_33</DOCNO>
            	<TEXT>Nonetheless, for other biotech investor enthusiasts out there, the wide world offers an interesting and expanded set of investment options.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_1684_112_34</DOCNO>
            	<TEXT>Bon voyage, trade responsibility, do your own DD, and Im not your financial advisor 
    3
      </TEXT>
        </DOC>
